Caribou Biosciences (CRBU) Profit After Tax (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Profit After Tax of -$126000.0 for Q1 2026, up 99.69% year-over-year from -$63099.2 in Q1 2025, and up 99.52% quarter-over-quarter from -$26.5 million in Q4 2025.
Caribou Biosciences (CRBU) Profit After Tax (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Profit After Tax for 7 consecutive years, with -$126000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax rose 99.69% year-over-year to -$126000.0; the TTM figure through Mar 2026 stood at -$26.7 million (up 75.63% YoY), while the FY2025 annual figure was -$148.1 million, up 0.51% from the prior year.
- Profit After Tax improved to -$126000.0 in Q1 2026 per CRBU's latest filing, from -$26.5 million in the prior quarter.
- Across five years, Profit After Tax topped out at $71.0 million in Q4 2022 and bottomed at -$40.1 million in Q1 2025.
- Historically, Profit After Tax has averaged -$9.2 million across 5 years, with a median of -$492000.0 in 2022.
- Annual changes were most pronounced in 2022 — Profit After Tax soared 484.49% — and 2025, when it slumped 11286.08%.
- Caribou Biosciences' Profit After Tax stood at $71.0 million in 2022, then slumped by 148.57% to -$34.5 million in 2023, then dropped by 4.4% to -$36.0 million in 2024, then rose by 26.37% to -$26.5 million in 2025, then soared by 99.52% to -$126000.0 in 2026.
- Business Quant data shows CRBU's Profit After Tax at -$126000.0 in Q1 2026, -$26.5 million in Q4 2025, and $53000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Caribou Biosciences | 166.63 Mn | 54.31 Mn | - | -24.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.33 Mn |
| Mar 31, 2026 | -126,000.00 |
| Dec 31, 2025 | -26.53 Mn |
| Sep 30, 2025 | 53,000.00 |
| Jun 30, 2025 | -127,000.00 |
| Mar 31, 2025 | -40.08 Mn |
| Dec 31, 2024 | -36.02 Mn |
| Sep 30, 2024 | -33.58 Mn |
| Jun 30, 2024 | 3,000.00 |
| Mar 31, 2024 | -352,000.00 |
| Dec 31, 2023 | -34.51 Mn |
| Sep 30, 2023 | -9.85 Mn |
| Jun 30, 2023 | -406,000.00 |
| Mar 31, 2023 | 788,000.00 |
| Dec 31, 2022 | 71.05 Mn |
| Sep 30, 2022 | -26.65 Mn |
| Jun 30, 2022 | -492,000.00 |
| Mar 31, 2022 | -19.09 Mn |
| Dec 31, 2021 | -18.48 Mn |
| Sep 30, 2021 | -20.97 Mn |